Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

Stefan Faderl*, Deborah A. Thomas, Susan O'Brien, Guillermo Garcia-Manero, Hagop M. Kantarjian, Francis J. Giles, Charles Koller, Alessandra Ferrajoli, Srdan Verstovsek, Barbara Pro, Michael Andreeff, Miloslav Beran, Jorge Cortes, William Wierda, Ngoc Tran, Michael J. Keating

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

238 Scopus citations

Fingerprint

Dive into the research topics of 'Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science